Amplimmune (United States)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Pharmacology, Toxicology and Pharmaceutics 70.6×
• Biochemistry, Genetics and Molecular Biology 7.3×
• Computer Science 3.2×
• Immunology and Microbiology 1.3×
• Medicine 0.5×

By fractional works in all years, weighted toward what it does more of than the world: Epidemiology, Monoclonal Antibodies, Therapeutic Antibodies, Glycosylation, Tumor Microenvironment, Inflammation, Immunotherapy and Immunity.

By volume in 2022–2025: Pharmacogenetics and Drug Metabolism, Receptor Mechanisms and Signaling, Computational Drug Discovery Methods and CAR-T cell therapy research.

1. 1 Pharmacogenetics and Drug Metabolism Pharmacology 0 works
2. 2 Receptor Mechanisms and Signaling Molecular Biology 0 works
3. 3 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
4. 4 CAR-T cell therapy research Oncology 0 works
5. 5 Protein Degradation and Inhibitors Molecular Biology 0 works
6. 6 Immunotherapy and Immune Responses Immunology 0 works
7. 7 Ubiquitin and proteasome pathways Molecular Biology 0 works
8. 8 Ocular Oncology and Treatments Ophthalmology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 65% lower than in 2013–2017.

• National Institute of Standards and Technology
• Molecular Oncology (United States)
• Scientific Consulting Group
• NIST Center for Neutron Research
• Material Measurement Laboratory
• Center for Nanoscale Science and Technology
• Information Technology Laboratory
• Robotic Research (United States)